The MasSpec Pen, developed by researchers from University of Texas, Austin in the US, is a handheld instrument that gives surgeons precise diagnostic information about what tissue to cut or preserve during surgery.
The current methods for diagnosing cancers and determining the boundary between cancer and normal tissue during surgery, is slow and sometimes inaccurate.
Also Read
However, in tests on tissues removed from 253 human cancer patients, the MasSpec Pen took about 10 seconds to provide a diagnosis and was more than 96 per cent accurate.
The technology was also able to detect cancer in marginal regions between normal and cancer tissues that presented mixed cellular composition.
Living cells, whether they are healthy or cancerous, produce small molecules called metabolites. These molecules are involved in all the important processes of life - such as generating energy, growing and reproducing - as well as other useful functions such as removing toxins, researchers said.
Each type of cancer produces a unique set of metabolites and other bio markers that act as fingerprints.
"Since the metabolites in cancer and normal cells are so different, we extract and analyse them with the MasSpec Pen to obtain a molecular fingerprint of the tissue," said Livia Schiavinato Eberlin, assistant professor at University of Texas, Austin.
"What is incredible is that through this simple and gentle chemical process, the MasSpec Pen rapidly provides diagnostic molecular information without causing tissue damage," Eberlin said.
The molecular fingerprint obtained by the MasSpec Pen from an uncharacterised tissue sample is instantaneously evaluated by software, trained on a database of molecular fingerprints that was gathered from 253 human tissue samples.
The samples included both normal and cancerous tissues of the breast, lung, thyroid and ovary.
When the MasSpec Pen completes the analysis, the words "Normal" or "Cancer" automatically appear on a computer screen. For certain cancers, such as lung cancer, the name of a subtype might also appear.
The team also demonstrated that it accurately diagnoses cancer in live, tumour-bearing mice during surgery without causing any observable tissue harm or stress to the animals.
The study was published in the journal Science Translational Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)